Background: Two therapeutic options are currently available for patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. To date, there is still insufficient data on the efficacy of these 2 agents in patients with more severe disease. Objectives: This national, multicenter, retrospective real-life study was intended to determine the impact of nintedanib on the treatment of patients with severe IPF. Methods: All patients included had severe IPF and had to have at least 6 months of follow-up before and at least 6 months of follow-up after starting nintedanib. The aim of the study was to compare the decline in lung function before and after treatment. Patient survival after 6 months of therapy with nintedanib was assessed. Results: Forty-one patients with a forced vital capacity (FVC) ≤50% and/or a diffusing capacity of the lung for carbon monoxide (DLCO) ≤35% predicted at the start of nintedanib treatment were enrolled. At the 6-month follow-up, the decline of DLCO (both absolute and % predicted) was significantly reduced compared to the pretreatment period (absolute DLCO at the –6-month, T0, and +6-month time points (5.48, 4.50, and 5.03 mmol/min/kPa, respectively, p = 0.03; DLCO% predicted was 32.73, 26.54, and 29.23%, respectively, p = 0.04). No significant beneficial effect was observed in the other functional parameters analyzed. The 1-year survival in this population was 79%, calculated from month 6 of therapy with nintedanib. Conclusions: This nationwide multicenter experience in patients with severe IPF shows that nintedanib slows down the rate of decline of absolute and % predicted DLCO but does not have significant impact on FVC or other lung parameters.

1.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
2.
Harari S, Madotto F, Caminati A, Conti S, Cesana GC: Epidemiology of idiopathic pulmonary fibrosis in Northern Italy. PLoS One 2016; 11:e0147072.
3.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 2011; 377: 1760–1769.
4.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al: A phase 3 trial of Pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
5.
Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079–1087.
6.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
7.
Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Oqura T: Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013; 107: 1431–1437.
8.
Oltmanns U, Khan N, Palmowski K, Träger A, Wenz H, Heussel CP, et al: Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199–207.
9.
Chaudhuri N, Duck A, Frank R, Holme J, Leonard C: Real word experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med 2014; 108: 224–226.
10.
Salih GN, Shaker SB, Madsen HD, Bendatrup E: Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. Eur Clin Respir J 2016; 3: 32608.
11.
Sköld CM, Janson C, Elf AK, Fiaschi M, Wiklund K, Persson HL: A retrospective chart review of pirfenidone-treated patients in Sweden: the REPRIS study. Eur Clin Respir J 2016; 3: 32035.
12.
Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N: Real world esperiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med 2016; 5:E78.
13.
Bonella F, Kreuter M, Hagmeyer L, Neurohr C, Keller C, Kohlhaeufl MJ, et al: Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration 2016; 92: 98–106.
14.
Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, et al: Efficacy of pirfenidone for idiopathic pulmonary fibrosis; an Italian real life study. Respir Med 2015; 109: 904–913.
15.
Wuyts WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G: First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤ 50% of predicted value. Lung 2016; 194: 739–743.
16.
Harari S, Caminati A: Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. Eur Respir Rev 2015; 24: 420–427.
17.
Raghu G, Rochwerg B, Zhang Y, Cuoello Garcia CA, Azuma A, Behr J, et al: An official ATS/ERS/JRS/ALAT Clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192:e3–e19.
18.
Chu SC, Horiba K, Usuki J, Avila NA, Chen CC, Travis WD, et al: Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999; 115: 1041–1052.
19.
Taveira-DaSilva AM, Moss J: Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clin Epidemiol 2015; 7: 249–257.
20.
Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, et al: Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016; 193: 178–185.
21.
Ryerson CJ, Kolb M, Richeldi L, Lee J, Kimura T, Stowasser S, Poletti V: Effect of baseline GAP index stage on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2016; 193:A2691.
22.
Caminati A, Cassandro R, Harari S: Pulmonary hypertension in chronic interstitial lung diseases. Eur Respir Rev 2013; 22: 292–301.
23.
Frost AE, Barst RJ, Hoeper MM, Chang HJ, Frantz RP, Fukumoto Y, et al: Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant 2015; 34: 1366–1375.
24.
Meltzer EB, Noble P: Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008; 3: 8.
25.
Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR: Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604–610.
26.
Kolb M, Collard HR: Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev 2014; 23: 220–224.
27.
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al: Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543–548.
28.
Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK: Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538–542.
29.
Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, et al: Fibrotic idiopathic pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531–537.
30.
Egan J, Martinez F, Wells A, Williams T: Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005; 60: 270–273.
31.
Caminati A, Harari S: IPF: new insight in diagnosis and prognosis. Respir Med 2010; 104:S2–S10.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.